From AI oversight and device cybersecurity to outpatient growth and tariff pressure, these eight medtech trends are reshaping how devices are built, regulated, and used in 2026.
Blog Post
9 minute read
Oct 08, 2026
The medical device sector is moving through one of its most active periods of change in years. Regulation, reimbursement, trade policy, and technology are all shifting at once, and each shift touches how devices are designed, built, secured, and sold.
Some of the most important medtech industry trends for 2026 are commercial, like the steady migration of procedures out of the hospital. Others are technical, like the growing weight regulators place on AI oversight and cybersecurity.
Below, we break down eight medtech trends shaping the year and what each one means for manufacturers and the clinicians and patients who rely on their devices.
Learn more about what Impact can do for healthcare organizations by visiting our healthcare industry page.
8 MedTech Industry Trends Shaping 2026
These trends span the full device lifecycle, from design and regulatory submission through manufacturing, distribution, and postmarket support.
Artificial intelligence is no longer a niche feature in medical devices. The FDA reports it has authorized more than 1,600 AI-enabled medical devices for the U.S. market as of September 2026.
Regulators are building a framework to match. In January 2025, the FDA issued draft guidance on AI-enabled device software functions that covers the total product lifecycle, from design through postmarket monitoring.
The agency has also finalized guidance on predetermined change control plans (PCCPs). These plans let manufacturers define in advance how an AI model will be updated, which reduces the need for a new submission every time an algorithm improves.
For manufacturers, this raises the bar on data governance, model validation, and documentation. AI performance has to be demonstrated and monitored, not just claimed.
AI changes what happens after launch, too. Models can drift as patient populations and clinical practices change, so manufacturers need reliable processes for tracking real-world performance and acting on what the data shows.
2. Cybersecurity Is Now a Regulatory Requirement
Connected devices expand what clinicians can do, but they also expand the attack surface inside hospitals and patients' homes. Federal law now treats device cybersecurity as a condition of market entry.
Section 524B of the FD&C Act, in effect since December 29, 2022, requires manufacturers of "cyber devices" to submit a software bill of materials (SBOM), maintain a plan to monitor and address postmarket vulnerabilities, and provide processes for updates and patches.
The challenge is compounded by the environments devices operate in. Many hospitals still run older equipment alongside new connected systems, which makes coordinated vulnerability disclosure and timely patching a shared responsibility between manufacturers and their customers.
Security can no longer be addressed after launch. It has to be designed into the product architecture, the quality system, and the supply chain of every software component.
3. Procedures Continue Shifting to Outpatient and ASC Settings
The move from inpatient to outpatient care accelerated sharply this year. In its CY 2026 OPPS and ASC final rule, CMS began a three-year phase-out of the Medicare inpatient-only list, removing 285 mostly musculoskeletal procedures in the first year.
In the same rule, CMS added 560 procedures to the ambulatory surgical center (ASC) covered procedures list. The CY 2027 proposed rule, issued July 2, 2026, would remove another 638 services from the inpatient-only list.
The final rule eliminated five general exclusion criteria for ASC eligibility, converting them into nonbinding considerations for physicians. That gives clinicians more latitude to decide when a procedure is appropriate for an ambulatory setting.
ASCs operate with different space, staffing, and budget constraints than hospitals. Devices built for these settings need smaller footprints, faster setup, and a clear economic case for lower-cost sites of care.
4. Remote Monitoring Is Extending Care Into the Home
Some care is moving beyond the clinic entirely. Remote patient monitoring has become a meaningful growth area for device makers, and reimbursement is expanding to support it.
Starting in 2026, Medicare remote physiologic monitoring codes recognize data collected on as few as 2 to 15 days in a 30-day period. Previously, billing required at least 16 days of readings.
That change opens the door for shorter-term monitoring, such as post-surgical recovery or medication titration. It also increases the volume of patient data flowing from home devices into clinical systems, which raises the stakes for interoperability and data security.
Device design matters here too. Patients are the ones operating these devices day to day, so simple setup, reliable connectivity, and clear feedback have a direct effect on adherence and on the quality of data clinicians receive.
5. Robotics and Platform Ecosystems Are Redefining Competition
Surgical robotics is becoming more competitive as new systems enter the U.S. market. In December 2025, Medtronic received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, a category the company puts at roughly 230,000 procedures a year in the U.S.
Hugo had already been used in tens of thousands of procedures across more than 30 countries before its U.S. clearance, according to Medtronic. Its arrival adds a significant new option for hospitals evaluating robotic programs.
The hardware is only part of the offering. Hugo connects to a digital ecosystem for surgical video, tele-proctoring, and AI-driven postoperative insights.
This reflects a broader shift toward platforms that combine robotics, imaging, navigation, and software. Competitive advantage increasingly depends on the data and workflow tools surrounding a device, not just the device itself.
6. Trade Policy Is Reshaping Supply Chain Strategy
Tariffs have become one of the most persistent cost pressures facing manufacturers. According to a PwC trade leader quoted by MedTech Dive, the largest medtech companies face tariff impacts of $200 million to $500 million annually.
Uncertainty remains high. In February 2026, the Supreme Court ruled that the president lacked authority to impose tariffs under the International Emergency Economic Powers Act, and the administration responded with a broad 10% tariff under Section 122.
Meanwhile, the Commerce Department's Section 232 investigation into medical devices, launched in September 2025, was still open as of April 2026.
In response, manufacturers are diversifying suppliers, building multi-region production footprints, and investing in better visibility across their supply chains. Global pricing pressure, including volume-based procurement in China, adds to the need for flexible cost structures.
7. GLP-1 Therapies Are Changing Patient Pathways
The rapid adoption of GLP-1 receptor agonists is affecting device demand in ways few predicted a few years ago. A study of more than 17 million insured Americans published in JAMA Network Open found that bariatric surgery rates fell 25.6% between 2022 and 2023, while GLP-1 prescriptions for obesity more than doubled.
The effects extend beyond bariatrics. Changes in weight and metabolic health could influence demand for devices tied to diabetes, sleep apnea, orthopedics, and cardiovascular care over time.
Bariatric surgery remains the most effective intervention for substantial, sustained weight loss. The open question is how patients and clinicians will weigh surgery, medication, or a combination of the two as more long-term outcomes data becomes available.
Manufacturers in these categories are watching closely. The long-term picture is still forming, and portfolio strategies will need to adjust as real-world data matures.
8. Quality Systems Are Aligning With Global Standards
The FDA's Quality Management System Regulation (QMSR) took effect on February 2, 2026. It amends 21 CFR Part 820 and incorporates ISO 13485:2016 by reference, harmonizing U.S. requirements with those used by other regulators.
As part of the transition, the FDA retired its long-standing Quality System Inspection Technique. Manufacturers are updating procedures, training, and documentation to reflect the new inspection approach.
The practical impact varies by company. Organizations already certified to ISO 13485 may face a lighter lift, while those built around the legacy Quality System Regulation have more ground to cover.
For many organizations, QMSR is a chance to modernize. Digital quality systems, traceable design records, and connected manufacturing data make it easier to demonstrate compliance across multiple markets.
Taken together, these medtech trends point to an industry where regulatory, clinical, and operational decisions are increasingly connected. A change in reimbursement affects product design, and a change in trade policy affects pricing and portfolio strategy.
The Cybersecurity Component
Nearly every trend on this list carries a security dimension. As devices take on more software, more connectivity, and more data, the consequences of a vulnerability reach well beyond IT systems.
For patients, the risk is personal and immediate. In January 2025, the FDA warned that certain Contec and Epsimed patient monitors, used in both health care facilities and homes, contained vulnerabilities that could allow unauthorized remote control, along with a hidden backdoor that sent patient data outside the care environment.
The agency advised patients who relied on remote monitoring with those devices to stop using them and seek alternatives. That guidance shows how a single flawed device can interrupt care that patients depend on every day.
The growth of home-based monitoring raises the stakes further. A device in a patient's home sits outside the hospital's security controls, often on a personal network with limited protection.
For hospitals, the impact extends from individual devices to entire operations. A study published in the American Economic Journal: Economic Policy found that ransomware attacks reduced hospital patient volume by 17% to 24% during the first week, while in-hospital mortality among patients already admitted rose by 34% to 38%.
Connected devices can widen that exposure. Infusion pumps, imaging systems, and monitors often share networks with clinical and administrative systems, and older equipment may no longer receive security updates.
This is why security now sits at the center of both device design and procurement. The SBOMs and patch plans manufacturers provide under Section 524B give hospitals clearer insight into a device's risk before it ever reaches the floor.
Manufacturers and health systems who treat device security as a shared responsibility, through coordinated vulnerability disclosure, network segmentation, and lifecycle planning, will be better prepared to protect both patient safety and continuity of care.
Wrapping Up on MedTech Industry Trends
The medtech industry trends defining 2026 share a common thread. Devices are becoming more connected, more software-driven, and more closely regulated, while the settings where they are used continue to diversify.
Manufacturers who invest in secure, data-ready products and resilient operations will be better positioned for the changes still ahead. The medtech trends covered here will continue to evolve, and staying informed on each one will remain essential through 2027 and beyond.
Learn more about what Impact can do for healthcare organizations by visiting our healthcare industry page.
Andrew Mancini
Content Writer
Andrew Mancini is a Content Writer for Impact's in-house marketing team, where he plans content for the Impact insights hub, manages the publication schedule, drafts articles, Q&As, interview narratives, case studies, video scripts, and other content with SEO best practices. He is also the main contributor on a monthly cybersecurity news series, The Security Report, researching stories, writing the script, and delivering the report on camera.
